business
Pipeline
Autologous Immunotherapy
SNK01-US01 Clinical study in the U.S.
- Target disease : Combination Therapy of Refractory Cancer + Pembrolizumab or Avelumab
- Trial No. : NCT03941262 Learn more
- Discovery
- Preclinical
- Phase I
- Phase II
SNK01-N12a Clinical study in Korea
- Target disease : Combination therapy of non-small cell lung cancer + pembrolizumab
- Trial No. : KCT0003463 Learn more
- Discovery
- Preclinical
- Phase I
- Phase II
SNK01-TRN12a Clinical study in Korea
- Target disease : Combination therapy of non-small cell lung cancer + Chemotherapy or Cetuximab
- Trial No. : NCT04872634 Learn more
- Discovery
- Preclinical
- Phase I
- Phase II
SNK01-MX04 Clinical study in Mexico
- Target disease : Mild Cognitive Impairment (MCI) and Alzheimer’s Disease (AD)
- Discovery
- Preclinical
- Phase I
- Phase II
Allogenic Immunotherapy
- Target disease : Combination therapy of Metastatic Gastric Cancer + Trastuzumab/XP (Capecitabin + Cisplatin)
- Discovery
- Preclinical
- Phase I
- Phase II
- Target disease : Refractory Cancer to Conventional Therapy
- Trial No : NCT05990920 Learn more
- Discovery
- Preclinical
- Phase I
- Phase II
- Target disease : Metastatic or Locally Advanced Solid Tumors who failed to standard therapy
- Discovery
- Preclinical
- Phase I
- Phase II
CAR-NK
- Discovery
- Preclinical
- Phase I
- Phase II